AEGLEA BIOTHERAPEUTICS INC's ticker is AGLE and the CUSIP is 00773J103. A total of 85 filers reported holding AEGLEA BIOTHERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $1,425,000 | +106.5% | 300,000 | 0.0% | 0.16% | +1.2% |
| Q1 2022 | $690,000 | -51.6% | 300,000 | 0.0% | 0.16% | -58.1% |
| Q4 2021 | $1,425,000 | -40.3% | 300,000 | 0.0% | 0.38% | -14.5% |
| Q3 2021 | $2,385,000 | +14.2% | 300,000 | 0.0% | 0.45% | +23.8% |
| Q2 2021 | $2,088,000 | -12.1% | 300,000 | 0.0% | 0.36% | -16.4% |
| Q1 2021 | $2,376,000 | +0.6% | 300,000 | 0.0% | 0.43% | -5.1% |
| Q4 2020 | $2,361,000 | +11.0% | 300,000 | 0.0% | 0.46% | -2.6% |
| Q3 2020 | $2,127,000 | -23.4% | 300,000 | 0.0% | 0.47% | -30.6% |
| Q2 2020 | $2,775,000 | – | 300,000 | – | 0.67% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO | 279,678 | $2,587,000 | 10.00% |
| Aisling Capital Management LP | 1,691,151 | $15,643,000 | 5.97% |
| Samsara BioCapital, LLC | 967,500 | $8,949,000 | 2.88% |
| Bain Capital Life Sciences Investors, LLC | 2,700,000 | $24,975,000 | 2.62% |
| Soleus Capital Management, L.P. | 369,852 | $3,421,000 | 1.95% |
| Nantahala Capital Management | 3,204,830 | $29,645,000 | 0.89% |
| Lion Point Capital, LP | 300,000 | $2,775,000 | 0.67% |
| Abingworth LLP | 240,500 | $2,221,000 | 0.62% |
| Sio Capital Management, LLC | 211,104 | $1,953,000 | 0.57% |
| Orbimed Advisors | 4,015,524 | $37,144,000 | 0.52% |